Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III KEYNOTE-204 trial.
Recent Articles
Systemic Bevacizumab Improves Anemia, Reduces Bleeding in Hereditary Hemorrhagic Telangiectasia
Treatment with systemic bevacizumab reduced bleeding and significantly increased hemoglobin levels in patients with the rare bleeding disorder hereditary hemorrhagic telangiectasia (HHT), according to...
Can Risk-Adapted EPOCH-R Replace Intensive Therapy for Burkitt Lymphoma?
Adults with Burkitt lymphoma are typically treated with dose-intensive combination chemotherapy derived from pediatric leukemia regimens, which the study investigators noted is “acutely toxic...
DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma
Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
FDA Approves Tazemetostat for EZH2-Mutated Follicular Lymphoma
Tazemetostat, an enhancer of zeste homolog 2 (EZH2) gene inhibitor, was granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL)...
Study Supports Use of AHCT Over VMP as Intensification in Newly Diagnosed Myeloma
In patients with newly diagnosed myeloma, following induction chemotherapy, early autologous hematopoietic cell transplantation (AHCT) as intensification therapy prolonged progression-free survival (PFS), compared with...
Current Issue
July 2020 Bonus Mid-Year Edition, Volume 6 Issue 9
This issue features analysis of COVID-19-associated lymphopenia, coverage from the ASCO and EHA annual meetings, and more.
